The first advanced therapy medicinal product (ATMP) in Russia was registered by GENERIUM under the trade name EASYTENSE. It is an autologous product based on chondrocytes, the main cells of cartilage tissue, and is intended for the restoration of damage to the cartilage of the knee joint with a defect area of up to 10 square cm.
Chondrocytes isolated from a biopsy of a patient’s healthy cartilage are cultured in vitro at the licensed production facility of GENERIUM. The product is a three-dimensional structure made from the patient’s own chondrocytes – spheroids, implanted into the site of a cartilage tissue defect. Chondrocytes fill the defect area with components of the hyaline matrix, providing a regenerative effect.
The cellular product is produced individually for each patient and is intended exclusively for personalized use, which eliminates the risks of rejection and infection with foreign pathogens. The entire process from collecting biomaterial to transplanting cultured cells into the defect site takes an average of 4–8 weeks.
